Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

ItalyBack to Italy

Clinical trials in Legnano – page 100

2 907 clinical trials in Legnano, Italy across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

ItalyOur site in ItalyStudi-Clinici.it(opens in a new tab)
Legnano at a glance
2 907
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

2 907 trials in Legnano

Open in trial search

Metabolic dysfunction-associated steatohepatitis

Not yet recruiting

Study of efimosfermin alfa versus placebo in adults with compensated cirrhosis from metabolic dysfunction-associated steatohepatitis (MASH)

Investigational
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Efimosfermin alfa
  • Sponsor:Glaxosmithkline Research & Development Limited

Adenocarcinoma pancreas

Not yet recruiting

First‑Line Study of Zoldonrasib (RMC‑9805) Drug Combination vs Gemcitabine/Nab‑Paclitaxel in Patients with Metastatic KRAS G12D‑Mutated Pancreatic Cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Daraxonrasib
  • Sponsor:Revolution Medicines Inc.

Transitional cell carcinoma

Not yet recruiting

ctDNA‑guided Study of Enfortumab Vedotin plus Pembrolizumab in Untreated Patients with Advanced Urothelial Carcinoma

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Enfortumab Vedotin
  • Sponsor:Fondazione Policlinico Universitario Agostino Gemelli IRCCS

Plasma cell myeloma

Not yet recruiting

A Phase III Study of AZD0120 versus melphalan hydrochloride with lenalidomide maintenance in transplant‑eligible adults with newly diagnosed multiple myeloma

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:AZD0120
  • Sponsor:Astrazeneca AB

IgA nephropathy

Not yet recruiting

Study of ARGX-121 to Reduce Proteinuria in Adults with Primary IgA Nephropathy (IgAN)

Investigational
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:ARGX-121
  • Sponsor:Argenx

Pulmonary arterial hypertension+1

Not yet recruiting

Safety and Efficacy of Extended‑Release Tacrolimus (VI‑0106) in Adults with Pulmonary Arterial Hypertension and Functional Limitations

Investigational
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Tacrolimus
  • Sponsor:Vivus B.V.

Primary biliary cholangitis

Not yet recruiting

Safety and Efficacy of Saroglitazar Magnesium in Patients with Primary Biliary Cholangitis: A Long‑Term Randomized Placebo‑Controlled Study

Investigational
Countries:ItalyItaly
  • Participants:18–64 years
  • Substances:Saroglitazar hemimagnesium
  • Sponsor:Zydus Therapeutics Inc.

Diffuse large B-cell lymphoma+5

Not yet recruiting

Study of MDX2003 in Adults with Relapsed or Refractory B‑Cell Malignancies

InvestigationalNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:MDX2003
  • Sponsor:Modex Therapeutics Inc.

Metastatic malignant melanoma+2

Not yet recruiting

Methoxsalen (ECP) versus drug combination for steroid‑refractory immune‑related colitis or hepatitis in metastatic melanoma on checkpoint therapy

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Azathioprine
  • Sponsor:Therakos Europe Limited

Pulmonary arterial hypertension

Not yet recruiting

A Phase 3 Study of Once‑Daily Treprostinil Palmitil Inhalation Powder for Adults with Pulmonary Arterial Hypertension

Investigational
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Treprostinil Palmitil
  • Sponsor:Insmed Inc.

Retinal dystrophy

Not yet recruiting

A Study of ATSN-201 Gene Therapy for Patients with X-linked Retinoschisis (RS1-associated) to Assess Safety and Visual Function

InvestigationalNo placebo
Countries:ItalyItaly
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Ziloretgene parvec
  • Sponsor:Atsena Therapeutics Inc.

Clear cell renal cell carcinoma+2

Not yet recruiting

Phase 1/2 Study of pumitamig Alone or Combined with ipilimumab or cabozantinib in Patients with Advanced Renal Cell Carcinoma

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Cabozantinib
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

Other cities in Italy

The busiest research cities in the country

All 232 cities in Italy

Clinical research in Legnano

What the registry says about research in the country

01 Hematologic Oncology

Extensive research focusing on Multiple Myeloma treatments, including innovative therapies for relapsed and refractory cases. Studies evaluating new drug combinations and treatment approaches for better patient outcomes.

  • Melflufen therapy for elderly patients
  • Elranatamab monotherapy trials
  • Novel combination treatments for RRMM

Multiple ongoing trials testing various therapeutic combinations to improve survival rates.

02 Solid Tumors

Groundbreaking studies in lung cancer and breast cancer treatment, investigating novel immunotherapy combinations and targeted therapies.

  • Advanced NSCLC immunotherapy trials
  • HER2-positive breast cancer treatments
  • Colorectal cancer targeted therapies

Focus on personalized treatment approaches and biomarker-driven therapies.

03 Chronic Conditions

Innovative research in chronic kidney disease and HIV management, exploring new treatment strategies and medication combinations.

  • Non-diabetic kidney disease treatments
  • HIV antiretroviral therapy optimization
  • Ulcerative colitis interventions

Studies aimed at improving long-term patient outcomes and quality of life.

Back to ItalyAll countries
Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.